Bristol-Myers Squibb Shares Rise After Analyst Upgrade SAnd Positive Pipeline Outlook
Bristol-Myers Squibb Shares Rise After Analyst Upgrade SAnd Positive Pipeline Outlook
The analyst expressed confidence that Milvexian, a drug in development for atrial fibrillation, could achieve positive results in non-inferiority trials, further supporting the company's growth prospects. He also noted improved visibility on Bristol-Myers Squibb's financials, driven by positive momentum from recent product launches and growing clarity on cost control measures. As a result, he raised his earnings-per-share projections, expecting the company to reach EPS floor of $6 in the near future.Bristol-Myers Squibb Inc. (NYSE:BMY) shares saw are trading higher Monday. Jefferies analyst, Akash Tewari, raised his rating on the stock from Hold to Buy and increased the price target from $63 to $70. Here's what you need to know.
施贵宝公司（纽交所：BMY）的股票在周一交易上涨。Jefferies的分析师Akash Tewari将该股票的评级从持有提高到买入，并将价格目标从63美元提高到70美元。以下是您需要了解的信息。
What To Know: The analyst's upgrade comes after increased confidence in several aspects of Bristol-Myers Squibb's business, particularly its pipeline and upcoming product launches. Tewari highlighted three key reasons for the upgrade.
需要了解的事项：该分析师的升级是基于对施贵宝业务多个方面的信心增强，特别是其管道和即将推出的产品。Tewari强调了升级的三个关键原因。
Tewari believes Cobenfy (KarXT), a treatment for schizophrenia and bipolar disorder, is on track to become a $10 billion-plus drug. He is bullish on the drug's launch in schizophrenia, as well as its potential in treating Alzheimer's psychosis and bipolar disorder. He expects strong sales growth in the coming years, with a 2025 forecast of $215 million, significantly above consensus estimates.
Tewari认为Cobenfy（KarXT），一种治疗精神分裂症和双相障碍的药物，有望成为一个超过100亿美元的药物。他对该药物在精神分裂症中的推出持看好态度，以及其在治疗阿尔茨海默病精神病和双相障碍方面的潜力。他预计在未来几年将实现强劲的销售增长，预计2025年的销量为21500万美元，远高于市场共识预期。
The analyst expressed confidence that Milvexian, a drug in development for atrial fibrillation, could achieve positive results in non-inferiority trials, further supporting the company's growth prospects. He also noted improved visibility on Bristol-Myers Squibb's financials, driven by positive momentum from recent product launches and growing clarity on cost control measures. As a result, he raised his earnings-per-share projections, expecting the company to reach EPS floor of $6 in the near future.
该分析师表示信心，认为正开发的Milvexian，一种用于房颤的药物，能够在非劣效性试验中取得积极结果，进一步支持公司的增长前景。他还指出，施贵宝的财务状况得到了改善的可见性，这得益于近期产品推出带来的积极动力以及对成本控制措施的日益清晰。因此，他提高了每股收益的预期，预计公司将在不久的将来达到每股收益6美元的底线。
Additionally, the company's ongoing collaboration with Immatics N.V. remains intact, despite the recent termination of other partnership agreements, including the allogeneic and opt-in collaborations with BMS. While this move reflects ongoing portfolio prioritization efforts, the termination does not require Bristol-Myers Squibb to refund any of the upfront payments.
此外，尽管最近终止了与BMS的其他合作协议，包括异体和期权合作，公司的与Immatics N.V.的持续合作仍然完好。虽然这一举动反映了持续的投资组合优先排序工作，但终止并不要求施贵宝退还任何预付款项。
With a new price target of $70, Jefferies sees upside potential in Bristol-Myers Squibb's stock.
在70美元的新价格目标下，Jefferies认为施贵宝的股票存在上行潜力。
BMY Price Action: Bristol-Myers Squibb shares were up 0.14% at $55.86 at the time of writing, according to Benzinga Pro.
BMY股票走势：根据Benzinga Pro的信息，施贵宝的股票在撰写时上涨0.14%，报55.86美元。
- IonQ, Quantum Computing And Rigetti Computing Shares Are Soaring Monday: What's Going On?
- IonQ, 量子计算概念和Rigetti Computing的股票在星期一飙升：发生了什么？
Image Via Shutterstock.
图片来自Shutterstock。